Assessment of hormonal status in polycystic ovary syndrome in adolescent girls
Abstract
PCOS is a multifactorial heterogeneous disease associated with endocrine, reproductive and metabolic manifestations. Polycystic ovarian syndrome (PCOS) is a 6-21% cause of infertility. The formation of PCOS and the manifestation of its clinical manifestations begin in adolescence. Objective of study: to investigate the hormone status features in adolescent girls with polycystic ovarian syndrome. Material and methods: The clinical and laboratory examination was provided to 112 adolescent girls aged 14 to 18 years. These included 72 patients with PCOS (study group I) and 40 virtually healthy girls of similar age with normal parameters of physical
and sexual development (comparison group II). The study of hormone status was done at the follicular and luteal phases using a microplate reader RT- 2100C. Conclusions: The study of reproductive system hormones and AMH plays a largely confirmatory role in the diagnosis of polycystic ovarian syndrome. In a patient with an ultrasound diagnosis of polycystic ovaries, estradiol, testosterone and progesterone can confirm the clinical diagnosis but they cannot exclude it. Alternatively, an increase in AMH is not a reliable indicator of polycystic ovarian syndrome, but it can detect the disease in its early stages.
References
Сутурина, Л.В. Гипоталамический синдром: основные звенья патогенеза, диагностика,патогенетическая терапия и прогноз : автореф. дис.... докт. мед. наук : 14.00.01 / Л.В. Сутурина. – Иркутск, 2002. - 46 с.
Meier, R.K. Polycystic ovary syndrome / R. K. Meier // Nurs. Clin. North Am. – 2018. Vol. 53, No 3, –р. 407-420.
Varanasi, L.C. Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16-29 years / L.C. Varanasi, A. Subasinghe, Y.L. Jayasinghe // Aust. N. Z. J. Obstet. Gynecol. – 2018. Vol. 58, – р. 222-233.
Cappelli, V. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS / V. Cappelli, M.C. Musacchio, A. Bulfoni [et al.] // Eur. Rev. Med. Pharmacol. Sci., – 2017. – р. 15-29.
Tehrani, F.R. Relationships between biochemical markers of hyperandrogenism and metabolic parameters in women with polycystic ovary syndrome: A systematic review and meta-analysis / F.R. Tehrani, R. Bidhendi-Yarandi, S. Behboudi-Gandevani [et al.] // Horm. Metab. Res. – 2019. – Vol. 51, No1, – р. 22-34.
Ibanez, L. An international consortium apdate: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence / L. Ibanez, Sh.E. Oberfield, S.F. Witchel [et al.] // Horm Res Paediatr. – 2017. Vol. 8896, – p. 371-395. DOI: 10.1159/000479371.
Pediatric and adolescent gynecology: evidence-basedclinical practice/ed. Sultan C., 2nd, revised and extendededition. Endocr Dev. Basel, Karger, 2012, Vol. 22, p. 181–193.
Crisosto, N. Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome / N. Crisosto, E. Codner, M. Maliqueo [et al.] // J. Clin. Endocrinol. Metab. – 2007. Vol. 92, – p. 2739-2743.
La Marca, A.V. Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause / A.V. La Marca, S. Leo De, Giulini [et al.] // J. Soc. Gynecol. Investig. – 2005. Vol. 12, – p. 545-548.
Lee, M.M. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood / M.M. Lee, P.K. Donahoe, T. Hasegawa [et al.] // J. Clin. Endocrinol. Metab. – 1996. Vol. 81, – p. 571-576.
Van Rooij, I.A. AntiMullerian hormone is a promising predictor for the occurrence of the menopausal transition / I.A. Van Rooij, I. Tonkelaar, F.J. Broekmans [et al.] // Menopause. – 2004. Vol. 11, – p. 601-606.
Venturoli, S. Flamigni Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence / S. Venturoli, E. Porcu, R. Fabbri [et al.] // Pediatr. Res. – 1995. Vol. 38 (6), – p. 974-980.
Hehenkamp, W.J. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation / W.J. Hehenkamp, C.W. Looman, A.P. Themmen [et al.] // J. Clin. Endocrinol. Metab. – 2006. Vol. 91, – p. 4057-4063.
La Marca, A. Anti-Mullerian hormone (AMH): what do we still need to know? / A. La Marca, F.J. Broekmans, A. Volpe [et al.] // Hum. Reprod. – 2009. Vol. 2 (9), – p. 2264-2275.
Streuli, I. Serum anti-Mullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids / I. Streuli, T. Fraisse, C. Pillet [et al.] // Fertil. Steril. – 2008. Vol. 90, – p. 395-400.
Cook, C.L. Relationship between serum mullerian – Inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women / C.L. Cook, Y. Siow, A.G. Brenner [et al.] // Fertil. Steril. – 2002. Vol. 77, – p. 141-146.
Eldar-Geva, T. Dynamic assays of inhibin B, anti – Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome / T. Eldar-Geva, A. Ben-Chetrit, I.M. Spitz [et al.] // Hum. Reprod. – 2005. Vol. 20, – p. 3178-3183.
Wachs, D.S. Serum anti–mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women / D.S. Wachs, M.S. Coffler, P.J. Malcom [et al.] // J. Clin. Endocrinol. Metab. – 2007. Vol. 92, – p. 1871-1874.
Dewailly, D. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries / D. Dewailly, H. Gronier, E. Poncelet [et al.] // Hum. Reprod. – 2011. Vol. 11 (26), – p. 3123-3129.
Eilertsen, T.B. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? / T.B. Eilertsen, E. Vanky, S.M. Carlsen // Hum. Reprod. – 2012. Vol. 27 (8), – p. 2494-2502.
Homburg, R. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study / R. Homburg, A. Ray, P. Bhide [et al.] // Hum. Reprod. – 2013. Vol. 4 (28), – p. 1077-1083.
Iliodromiti, S. Can Anti-Mullerian Hormone Predict the Diagnosis of Polycystic Ovary Syndrome? A Systematic Review and Meta-Analysis of Extracted Data / S. Iliodromiti, T.W. Kelsey, R.A. Anderson [et al.] // J. Clin. Endocrinol. Metab. – 2013. Vol. 98 (8), – p. 3332-3340.
Piltonen, T. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome / T. Piltonen, L. Morin-Papunen, R. Koivunen [et al.] // Hum Reprod. – 2005. Vol. 20(7), – p. 1820-1826. https://doi.org/10.1093/humrep/deh850
Keywords
hormonal status
dolescence polikistoz yumurtalıq sindromu
hormonal status
yeniyetməlik dövrü синдром поликистоза яичников
гормональный статус
подростковый возраст
Most read articles by the same author(s)
- N.M. Kamilova, I.G. Kafarov, R.K. Abbasova, Identification of pelvic organ prolapse and urogenital disorders in women without physical examination , Actual Questions of Modern Gynecology and Perinatology : Vol. 10 No. 1 (2023): Actual Questions o Modern Gynaecology and Perinatology
- N.M. Kamilova, G.M. Khalilova, Adolescent obesity: nutrition, physical activity and reproductive health , Actual Questions of Modern Gynecology and Perinatology : Vol. 9 No. 3 (2022): Actual questions of modern gynaecology and perinatology
- N.M. Kamilova, H.M. Mirzoeva, G.S. Mammadova, Principles of treatment tactics in chronic arterial hypertension in pregnant women , Actual Questions of Modern Gynecology and Perinatology : Vol. 9 No. 3 (2022): Actual questions of modern gynaecology and perinatology
- N.M. Kamilova, G.S. Məmmədova, Prognostic value of macro- and micronutrient studies in arterial hypertension , Actual Questions of Modern Gynecology and Perinatology : Vol. 10 No. 4 (2023): Actual questions of modern gynaecology and perinatology